We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Urology

Urology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Breakthrough ADC-Based Combination Therapy Achieves Over 95% Disease Control in Advanced Urothelial Cancer
OncologyAntibody-drug conjugateclinical trial

Breakthrough ADC-Based Combination Therapy Achieves Over 95% Disease Control in Advanced Urothelial Cancer

By MedXY|Oct 24, 2025

Datroway combined with rilvegostomig demonstrates impressive tumor response and disease control in advanced urothelial carcinoma, heralding a new therapeutic option in first- and second-line settings.

Enhancing Postoperative Sexual Readiness in Urogynecologic Surgery: Insights from a Randomized Trial
newsPostoperative Caresexual health

Enhancing Postoperative Sexual Readiness in Urogynecologic Surgery: Insights from a Randomized Trial

By MedXY|Oct 24, 2025

A recent trial evaluates the effectiveness of counseling interventions on patient preparedness and sexual outcomes after pelvic surgeries.

Developing a Patient-Centered Counseling Tool for Resuming Sexual Activity After Pelvic Reconstructive Surgery: A Qualitative and Cognitive Interview Approach
OB/GYN & Women's Healthqualitative research

Developing a Patient-Centered Counseling Tool for Resuming Sexual Activity After Pelvic Reconstructive Surgery: A Qualitative and Cognitive Interview Approach

By MedXY|Oct 24, 2025

A novel, evidence-based counseling tool was developed to guide patients in safely resuming sexual activity after pelvic reconstructive surgery. The tool integrates patient perspectives and expert input, addressing safety, discomfort, and re

ESD 2025 Consensus: Modern Management of Urinary Stones — Practical Recommendations for Clinicians
UrologyConsensus

ESD 2025 Consensus: Modern Management of Urinary Stones — Practical Recommendations for Clinicians

By MedXY|Oct 24, 2025

The ESD 2025 expert consensus updates diagnosis, prevention and interventional care for urinary stones—prioritizing metabolic evaluation, morpho‑compositional stone analysis, pressure/temperature safety in endourology, suction-enabled RIRS,

Impact of Enzalutamide on PSA Dynamics and Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights from the ARCHES Trial Secondary Analysis
Oncologyandrogen deprivation therapyEnzalutamide

Impact of Enzalutamide on PSA Dynamics and Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights from the ARCHES Trial Secondary Analysis

By MedXY|Oct 21, 2025

This secondary analysis of the ARCHES trial demonstrates that enzalutamide plus ADT improves progression-free and overall survival in mHSPC patients across PSA levels, with undetectable PSA strongly predicting favorable outcomes.

Cribriform Morphology’s Impact on Long-term Metastasis Risk in Prostate Cancer: Insights from the PROTECT Trial
Oncologyprostate cancerRadiotherapy

Cribriform Morphology’s Impact on Long-term Metastasis Risk in Prostate Cancer: Insights from the PROTECT Trial

By MedXY|Oct 21, 2025

A secondary analysis of the PROTECT trial reveals cribriform-positive prostate cancer significantly elevates 15-year metastasis risk, with radiotherapy plus neoadjuvant ADT reducing this risk more effectively than surgery or active monitori

Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis
Clinical Updatesimmunotherapyneoadjuvant therapy

Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis

By MedXY|Oct 23, 2025

Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients in

Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial
newsOligometastatic DiseaseRadiotherapy

Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial

By MedXY|Oct 15, 2025

A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiot

Obesity Interventions and Male Fertility: Unraveling the Effects of Weight Loss on Reproductive Health
Diabetes & Endocrinologylifestyle interventionsmale fertility

Obesity Interventions and Male Fertility: Unraveling the Effects of Weight Loss on Reproductive Health

By MedXY|Oct 12, 2025

This systematic review and meta-analysis evaluates the effects of obesity interventions—lifestyle modification, pharmacotherapy, and bariatric surgery—on male fertility, highlighting improvements with lifestyle changes and limited benefits

Vaginal Lasers in Stress Urinary Incontinence: Evaluating Efficacy and Safety through an Abridged Cochrane Review
newsmeta-analysisstress urinary incontinence

Vaginal Lasers in Stress Urinary Incontinence: Evaluating Efficacy and Safety through an Abridged Cochrane Review

By MedXY|Oct 12, 2025

This article reviews current evidence from a Cochrane systematic review on vaginal laser therapy for stress urinary incontinence in women, highlighting uncertain efficacy and safety profiles compared to sham and other treatments.

Biparametric MRI Matches Multiparametric MRI for Prostate Cancer Diagnosis: Insights from the PRIME Trial
newsprostate cancer

Biparametric MRI Matches Multiparametric MRI for Prostate Cancer Diagnosis: Insights from the PRIME Trial

By MedXY|Oct 10, 2025

The PRIME trial demonstrates that biparametric MRI, omitting contrast enhancement, is noninferior to multiparametric MRI in detecting clinically significant prostate cancer, offering a faster, cost-effective alternative potentially transfor

Microsurgical Advances and Clinical Outcomes in Penile Replantation: Overcoming Complex Reconstructive Challenges
newsmicrosurgery

Microsurgical Advances and Clinical Outcomes in Penile Replantation: Overcoming Complex Reconstructive Challenges

By MedXY|Oct 6, 2025

This article reviews microsurgical techniques and patient outcomes in penile replantation, highlighting complications, innovative management strategies, and the critical need for standardized protocols to improve functional and aesthetic re

Underutilization of PARP Inhibitors in Metastatic Prostate Cancer With BRCA1/2 Alterations: Insights from a US Real-World Cohort
newsmetastatic prostate cancerPARP inhibitors

Underutilization of PARP Inhibitors in Metastatic Prostate Cancer With BRCA1/2 Alterations: Insights from a US Real-World Cohort

By MedXY|Oct 4, 2025

Despite proven survival benefit, nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations did not receive PARP inhibitors in a US real-world study, highlighting critical gaps in treatment ac

PSMA PET-Guided Intensification of Salvage Radiotherapy Enhances Outcomes Post-Radical Prostatectomy: Insights from a Phase 2 RCT
newsprostate cancerPSMA-PET

PSMA PET-Guided Intensification of Salvage Radiotherapy Enhances Outcomes Post-Radical Prostatectomy: Insights from a Phase 2 RCT

By MedXY|Oct 6, 2025

A phase 2 randomized trial demonstrates that PSMA-PET-guided intensification of salvage radiotherapy after radical prostatectomy significantly improves failure-free survival without added toxicity.

Advancing Treatment in Oligometastatic Castration-Resistant Prostate Cancer: The GROUQ-PCS 9 Trial on SBRT Plus Standard Systemic Therapy
Clinical UpdatesEnzalutamidemetastasis-directed therapy

Advancing Treatment in Oligometastatic Castration-Resistant Prostate Cancer: The GROUQ-PCS 9 Trial on SBRT Plus Standard Systemic Therapy

By MedXY|Oct 9, 2025

The GROUQ-PCS 9 trial demonstrates that adding stereotactic body radiotherapy to standard androgen deprivation therapy and enzalutamide significantly prolongs radiographic progression-free survival in oligometastatic castration-resistant pr

How Often Should Men Have Sex? Harvard Study Links 21 Times a Month to Lower Prostate Cancer Risk
Family Medicine & Nutritioncancer preventionejaculation frequency

How Often Should Men Have Sex? Harvard Study Links 21 Times a Month to Lower Prostate Cancer Risk

By MedXY|Oct 8, 2025

A large Harvard study finds that frequent ejaculation—about 21 times a month—is associated with a significantly reduced risk of prostate cancer among men, offering new insights into modifiable factors for prevention.

Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223
OncologyEnzalutamidemetastatic castration-resistant prostate cancer

Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223

By MedXY|Oct 8, 2025

The PEACE-3 trial demonstrates that adding radium-223 to enzalutamide significantly improves radiological progression-free survival and suggests an overall survival benefit in metastatic castration-resistant prostate cancer with bone metast

Rizedisben Enhances Nerve Visualization in Minimally Invasive Prostate Surgery: Insights from a Phase 1 Dose-Escalation Trial
General Surgeryfluorescence-guided surgery

Rizedisben Enhances Nerve Visualization in Minimally Invasive Prostate Surgery: Insights from a Phase 1 Dose-Escalation Trial

By MedXY|Oct 7, 2025

This phase 1 trial identifies 3.0 mg/kg as the optimal safe and effective dose of rizedisben, a novel myelin-binding fluorophore, enhancing sustained intraoperative nerve fluorescence during robot-assisted laparoscopic radical prostatectomy

Unveiling the Hidden Risks of 5G Radiation: Impacts on Male Fertility
Public Healthhealth risksmale fertility

Unveiling the Hidden Risks of 5G Radiation: Impacts on Male Fertility

By MedXY|Oct 7, 2025

Recent animal studies suggest daily 5G phone radiation exposure may significantly impair sperm quality, raising concerns over modern lifestyle and reproductive health.

Behavioral Therapy Matches Drug Efficacy for Overactive Bladder in Parkinson’s Disease: Insights from a Randomized Noninferiority Trial
Clinical UpdatesBehavioral therapyParkinson disease

Behavioral Therapy Matches Drug Efficacy for Overactive Bladder in Parkinson’s Disease: Insights from a Randomized Noninferiority Trial

By MedXY|Oct 7, 2025

A 12-week randomized trial demonstrates that behavioral therapy is noninferior to solifenacin in treating overactive bladder symptoms in Parkinson disease, with fewer adverse effects, supporting behavioral therapy as a frontline treatment o

Prev
5 / 8
1…345678
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles